Рунимотамаб

Runimotamab

МНН

Rec. INN (наименование, зарегистрированное ВОЗ)

CAS

2361325-98-4

Химическое название

immunoglobulin G1-kappa, anti-[Homo sapiens ERBB2 (epidermal growth factor receptor 2, receptor tyrosine protein kinase erbB-2, EGFR2, HER2, HER-2, p185cerbB2, NEU, CD340)] and anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)], monoclonal antibody, bispecific;
gamma1 heavy chain anti-ERBB2 (1-450) [VH anti-ERBB2 (Homo sapiens IGHV3-66*01 (81.6%) -(IGHD) -IGHJ4*01 (100%)) CDR-IMGT [8.8.13] (26-33.51-58.97-109) (1-120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1, G1v30 CH2 G84.4, G1v32 CH3 W22 (CH1 R120>K (217) (121-218), hinge 1-15 (219-233), CH2 N84.4>G (300) (234-343), CH3 E12 (359), M14 (361), T22>W (369) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with kappa light chain anti-ERBB2 (1'-214') [V-KAPPA anti-ERBB2 (Homo sapiens IGKV1-39*01 (86.3%) -IGKJ1*01 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
gamma1 heavy chain anti-CD3E (1''-449'') [VH anti-CD3E (Mus musculus IGHV1-66*01 (82.7%) -(IGHD) -IGHJ2*01 (86.7%)/Homo sapiens anti-CD3E IGHV1-3*01 (82.7%) -(IGHD) -IGHJ4*01 (100%)) CDR-IMGT [8.8.12] (26-33.51-58.97-108) (1''-119'') -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1, G1v30 CH2 G84.4, G1v33 CH3 S22, A24, V86 (CH1 R120>K (216) (120''-217''), hinge 1-15 (218''-232''), CH2 N84.4>G (299) (233-342), CH3 E12 (358), M14 (360), T22>S (368), L24>A (370), Y86>V (409) (343''-447''), CHS (448''-449'') (120''-449'')], (222''-219''')-disulfide with kappa light chain anti-CD3E (1'''-219''') [V-KAPPA anti-CD3E (Homo sapiens IGKV4-1*01 (91.8%) -IGKJ1*01 (100%)) CDR-IMGT [12.3.8] (27-38.56-58.95-102) (1'''-112''') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113'''-219''')]; dimer (229-228'':232-231'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, non-glycosylated

Структура

Структура Рунимотамаб

Иностранные названия

Поделиться этой страницей

Подробнее по теме

Узнайте дополнительные сведения о действующем веществе Рунимотамаб: